A team at the University of Duisburg‑Essen reported an automated stirred‑tank bioreactor method to produce induced pluripotent stem cell‑derived lung organoids at scale. The protocol yields large numbers of free‑floating lung mini‑organs that capture multicellular structure and can be used for disease modeling and drug testing. Lead author Diana Klein said the key outcome is reproducible, automatable production that better represents in‑vivo lung tissue compared with traditional cell lines. Organoids can accelerate preclinical screening and potentially enable patient‑specific testing when derived from patient iPSCs. Stirred bioreactors lower hands‑on manufacturing barriers and could integrate with high‑throughput assays, supporting earlier, more predictive assessments of pulmonary therapeutics.